Summary of progression-free survival and overall survival in dmCODOX-M/IVAC study
| . | No. progression or death/total . | 2-year PFS (95% CI) . | Hazard ratio (95% CI), P . | No. death/total . | 2-year OS (95% CI) . | Hazard ratio (95% CI), P . |
|---|---|---|---|---|---|---|
| All patients | 45/110 | 60% (51%-69%) | 40/110 | 63% (54%-72%) | ||
| Low risk versus high risk | 0.39 (0.21-0.72), .003 | 0.33 (0.17-0.63), <.001 | ||||
| Low risk | 6/33 | 85% (73%-97%) | 4/33 | 88% (77%-99%) | ||
| High risk | 39/77 | 49% (38%-60%) | 36/77 | 52% (41%-63%) | ||
| BL versus DLBCL | 0.77 (0.43-1.38), .38 | 0.76 (0.41-1.40), .38 | ||||
| BL | 19/53 | 64% (51%-77%) | 17/53 | 67% (54%-80%) | ||
| DLBCL | 26/57 | 55% (42%-68%) | 23/57 | 59% (46%-72%) | ||
| Age 65 y or younger versus age older than 65 y | 0.13 (0.05-0.36), <.001 | 0.11 (0.04-0.32), <.001 | ||||
| 65 y or less | 33/95 | 65% (55%-75%) | 29/95 | 69% (60%-78%) | ||
| Older than 65 y | 12/15 | 25% (2%-48%) | 11/15 | 25% (2%-48%) | ||
| Presence of t(14,18) | 0.18 (0.055-0.57), .004 | 0.19 (0.055-0.64), .008 | ||||
| No evidence | 33/93 | 65% (55%-75%) | 29/93 | 73% (64%-82%) | ||
| Present | 8/10 | 20% (0%-45%) | 7/10 | 40% (10%-70%) | ||
| Unknown | 7 | 11 | ||||
| BL versus DLBCL* | 0.33 (0.13-0.82), .017 | 0.38 (0.14-1.01), .052 | ||||
| BL | 19/53 | 64% (51%-77%) | 17/53 | 67% (54%-80%) | ||
| DLBCL* | 11/15 | 27% (5%-49%) | 9/15 | 40% (15%-65%) |
| . | No. progression or death/total . | 2-year PFS (95% CI) . | Hazard ratio (95% CI), P . | No. death/total . | 2-year OS (95% CI) . | Hazard ratio (95% CI), P . |
|---|---|---|---|---|---|---|
| All patients | 45/110 | 60% (51%-69%) | 40/110 | 63% (54%-72%) | ||
| Low risk versus high risk | 0.39 (0.21-0.72), .003 | 0.33 (0.17-0.63), <.001 | ||||
| Low risk | 6/33 | 85% (73%-97%) | 4/33 | 88% (77%-99%) | ||
| High risk | 39/77 | 49% (38%-60%) | 36/77 | 52% (41%-63%) | ||
| BL versus DLBCL | 0.77 (0.43-1.38), .38 | 0.76 (0.41-1.40), .38 | ||||
| BL | 19/53 | 64% (51%-77%) | 17/53 | 67% (54%-80%) | ||
| DLBCL | 26/57 | 55% (42%-68%) | 23/57 | 59% (46%-72%) | ||
| Age 65 y or younger versus age older than 65 y | 0.13 (0.05-0.36), <.001 | 0.11 (0.04-0.32), <.001 | ||||
| 65 y or less | 33/95 | 65% (55%-75%) | 29/95 | 69% (60%-78%) | ||
| Older than 65 y | 12/15 | 25% (2%-48%) | 11/15 | 25% (2%-48%) | ||
| Presence of t(14,18) | 0.18 (0.055-0.57), .004 | 0.19 (0.055-0.64), .008 | ||||
| No evidence | 33/93 | 65% (55%-75%) | 29/93 | 73% (64%-82%) | ||
| Present | 8/10 | 20% (0%-45%) | 7/10 | 40% (10%-70%) | ||
| Unknown | 7 | 11 | ||||
| BL versus DLBCL* | 0.33 (0.13-0.82), .017 | 0.38 (0.14-1.01), .052 | ||||
| BL | 19/53 | 64% (51%-77%) | 17/53 | 67% (54%-80%) | ||
| DLBCL* | 11/15 | 27% (5%-49%) | 9/15 | 40% (15%-65%) |
Indicates DLBCL with t(8;14)+, t(14;18)+, or 3q27 rearrangement.